Form 4: Larimar Therapeutics Director Acquires 19,000 Stock Options
SEC Form 4 Filing
Director Frank E. Thomas acquired 19,000 stock options in Larimar Therapeutics, Inc. on May 29, 2024.
Summary
- Frank E. Thomas, a director of Larimar Therapeutics, Inc., acquired 19,000 stock options on May 29, 2024.
- The options have an exercise price of $7.07.
- The options vest on the earlier of May 29, 2025, or the date of the company's next annual meeting of stockholders, contingent upon continued service on the Board of Directors.
- The options expire on May 29, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director, which doesn't inherently indicate positive or negative sentiment.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of the stock option acquisition. |
| 05/29/2025 | Earliest vesting date for the stock options. |
| 05/29/2034 | Expiration date of the stock options. |
| 05/31/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.